Cargando…
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes
BACKGROUND: According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both amyloid-β (Aβ) and phosphorylated tau protein (p-tau) deposition—assessed interc...
Autores principales: | Carandini, Tiziana, Arighi, Andrea, Sacchi, Luca, Fumagalli, Giorgio G., Pietroboni, Anna M., Ghezzi, Laura, Colombi, Annalisa, Scarioni, Marta, Fenoglio, Chiara, De Riz, Milena A., Marotta, Giorgio, Scarpini, Elio, Galimberti, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794758/ https://www.ncbi.nlm.nih.gov/pubmed/31615545 http://dx.doi.org/10.1186/s13195-019-0543-7 |
Ejemplares similares
-
Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage
por: Pietroboni, Anna M., et al.
Publicado: (2022) -
Facing the digital divide into a dementia clinic during COVID-19 pandemic: caregiver age matters
por: Arighi, Andrea, et al.
Publicado: (2021) -
Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease
por: Fumagalli, Giorgio G., et al.
Publicado: (2020) -
Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation
por: Arighi, Andrea, et al.
Publicado: (2022) -
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis
por: Floro, Stefano, et al.
Publicado: (2022)